{
    "id": 30775,
    "fullName": "ROS1 F2004V",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ROS1 F2004V lies within the protein kinase domain of the Ros1 protein (UniProt.org). F2004V has been demonstrated to confer resistance to Ros1 tyrosine kinase inhibitors in the context of a Ros1 fusion (PMID: 28717217, JCO Precision Oncology, Jun 2019), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2020).",
            "references": [
                {
                    "id": 16046,
                    "pubMedId": null,
                    "title": "Dramatic Response to Lorlatinib in a Patient With CD74-ROS1-Positive Lung Adenocarcinoma With Acquired F2004V Mutation",
                    "url": "https://ascopubs.org/doi/full/10.1200/PO.19.00013"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11368,
                    "pubMedId": 28717217,
                    "title": "TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28717217"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6098,
        "geneSymbol": "ROS1",
        "terms": [
            "ROS1",
            "c-ros-1",
            "MCF3",
            "ROS"
        ]
    },
    "variant": "F2004V",
    "createDate": "08/21/2019",
    "updateDate": "03/05/2020",
    "referenceTranscriptCoordinates": {
        "id": 182166,
        "transcript": "NM_002944",
        "gDna": "chr6:g.117317268A>C",
        "cDna": "c.6010T>G",
        "protein": "p.F2004V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 18183,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring CD74-ROS1 developed progression while being treated with Rozlytrek (entrectinib) and through cell-free DNA analysis, was found to have acquired ROS1 F2004V (JCO Precision Oncology, Jun 2019).",
            "molecularProfile": {
                "id": 33045,
                "profileName": "CD74 - ROS1 ROS1 F2004V"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16046,
                    "pubMedId": null,
                    "title": "Dramatic Response to Lorlatinib in a Patient With CD74-ROS1-Positive Lung Adenocarcinoma With Acquired F2004V Mutation",
                    "url": "https://ascopubs.org/doi/full/10.1200/PO.19.00013"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18184,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring CD74-ROS1 and ROS1 F2004V was resistant to treatment with Alunbrig (brigatinib) (JCO Precision Oncology, Jun 2019).",
            "molecularProfile": {
                "id": 33045,
                "profileName": "CD74 - ROS1 ROS1 F2004V"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16046,
                    "pubMedId": null,
                    "title": "Dramatic Response to Lorlatinib in a Patient With CD74-ROS1-Positive Lung Adenocarcinoma With Acquired F2004V Mutation",
                    "url": "https://ascopubs.org/doi/full/10.1200/PO.19.00013"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18185,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring CD74-ROS1 and ROS1 F2004V was sensitive to treatment with Lorbrena (lorlatinib), demonstrating disease control for 6 months after treatment and a systemic response (JCO Precision Oncology, Jun 2019).",
            "molecularProfile": {
                "id": 33045,
                "profileName": "CD74 - ROS1 ROS1 F2004V"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16046,
                    "pubMedId": null,
                    "title": "Dramatic Response to Lorlatinib in a Patient With CD74-ROS1-Positive Lung Adenocarcinoma With Acquired F2004V Mutation",
                    "url": "https://ascopubs.org/doi/full/10.1200/PO.19.00013"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 33044,
            "profileName": "ROS1 F2004V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33045,
            "profileName": "CD74 - ROS1 ROS1 F2004V",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 182167,
            "transcript": "XM_011536054",
            "gDna": "chr6:g.117318213A>C",
            "cDna": "c.6010T>G",
            "protein": "p.F2004V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 182165,
            "transcript": "XM_011536049",
            "gDna": "chr6:g.117318213A>C",
            "cDna": "c.6010T>G",
            "protein": "p.F2004V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 182166,
            "transcript": "NM_002944",
            "gDna": "chr6:g.117317268A>C",
            "cDna": "c.6010T>G",
            "protein": "p.F2004V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}